April 2023 in “Tikrit Journal of Pharmaceutical Sciences” The study on 85 patients with ß-thalassemia in Kirkuk, Iraq, found that deferasirox, an oral iron chelator, effectively reduced serum ferritin levels in 55.3% of patients, indicating a decrease in iron overload. Some adverse effects were observed, including elevated serum creatinine in 25.8% of patients, elevated liver enzymes, and hair loss in 2 patients. Despite these side effects, deferasirox was generally well-tolerated, and its adverse effects could be managed by adjusting the dosage. The study concludes that deferasirox is a suitable treatment for managing iron overload in ß-thalassemia patients.
January 2023 in “Journal of The American Academy of Dermatology” Baricitinib helped most teenagers with severe hair loss regrow hair and had mild side effects.
37 citations,
October 2017 in “Clinical and Experimental Dermatology” Oral tofacitinib shows promise in treating atopic dermatitis and alopecia areata, but only slight improvement in vitiligo.
17 citations,
March 2016 in “Liver international” Men with advanced liver disease and high oestrone and low testosterone levels have worse health outcomes.
1 citations,
January 2016 in “Journal of Nepal Paediatric Society” A child with rickets and hair loss might have a rare type of rickets that doesn't improve much with usual vitamin D and calcium treatment.